Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

177.38USD
3:59pm EST
Change (% chg)

$1.12 (+0.64%)
Prev Close
$176.26
Open
$176.87
Day's High
$178.18
Day's Low
$175.97
Volume
1,411,261
Avg. Vol
993,424
52-wk High
$191.08
52-wk Low
$145.12

Select another date:

Mon, Dec 11 2017

Photo

Amgen's Kyprolis improves overall survival in blood cancer patients

Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

UPDATE 1-Amgen's Kyprolis improves overall survival in blood cancer patients

Dec 11 Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Amgen's Kyprolis improves overall survival in blood cancer patients

Dec 11 Amgen Inc said on Monday new data from a late-stage trial testing Kyprolis in combination with two other drugs showed improved overall survival rate in patients with blood cancer.

BRIEF-Kyprolis (Carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma

* KYPROLIS® (CARFILZOMIB) EXTENDED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN PHASE 3 ASPIRE TRIAL

BRIEF-Carmot Enters A Multi-Year Drug Discovery Collaboration With Amgen

* CARMOT ENTERS A MULTI-YEAR DRUG DISCOVERY COLLABORATION WITH AMGEN

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests

* BIOCARTIS AND AMGEN SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS

FDA approves heart protection claims for Amgen cholesterol drug

Amgen Inc can now promote the ability of its potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes, after U.S. health regulators approved adding those benefits to the medicine's prescribing label, the company said on Friday.

FDA approves heart protection claims for Amgen cholesterol drug

Dec 1 Amgen Inc can now promote the ability of its potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes, after U.S. health regulators approved adding those benefits to the medicine's prescribing label, the company said on Friday.

BRIEF-Amgen Says Aimovig Phase 3 Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention

* AIMOVIG™ (ERENUMAB) PHASE 3 STRIVE DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE DEMONSTRATE SIGNIFICANT, SUSTAINED EFFICACY IN MIGRAINE PREVENTION Source text for Eikon: Further company coverage:

Select another date: